Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
NEW YORK, April 30, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the expansion of its Equity Research platform with the appointment of Caroline Palomeque as a Senior Vice President and Senior Biotechnology Analyst.
Prior to joining Maxim Group, Ms. Palomeque was a Senior Research Analyst covering the Biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has equity research experience at Oppenheimer, JMP Securities, Goldman Sachs, and Natexis Bleichroeder. Ms. Palomeque has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins. She also coauthored several scientific papers which were peer-reviewed academic journals. “I am pleased to add someone with Caroline’s experience background to our Healthcare Platform. Healthcare is a core vertical at Maxim Group and Biotechnology is an important component,” said Anthony V. Vendetti, Executive Managing Director and Head of Equity Research at Maxim Group.
Ms. Palomeque holds an M.B.A. in Finance from Fordham University Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]
